CKChul Woo Kim

Chul Woo Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chul Woo Kim has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Ji Eun Kim

    Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

    4 shared publications
  • Byung Lan Lee

    3 shared publications
  • Heejung Kim

    Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

    3 shared publications
  • Hye Young Choi

    Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

    3 shared publications
  • J E Kim

    Department of Pathology, Seoul National University Boramae Hospital, Seoul, Korea

    3 shared publications
  • J H Paik

    Department of Pathology and the Tumour Immunity Medical Research Centre, Seoul National University College of Medicine

    3 shared publications

Latest Publications

  • Production of Colchicine Induced Tetraploids in Rye (Secale cereale L.)

    by Jong-Jin Hwang, Dea-Wook Kim, Chul-Woo Kim, Beum-Young Son, Seong-Beum Baek, Hyong-Ho Park, Ja-Hwan Ku, Jung-Tae Kim, Jin-Seok Lee, Jung-Kyung Moon, et al.

  • CpG Oligodeoxynucleotides Enhance the Activities of CD8+ Cytotoxic T-Lymphocytes Generated by Combined hMUC1 Vaccination and hNIS Radioiodine Gene Therapy

    by Yong Hyun Jeon, Yun Choi, Jaetae Lee, Chul Woo Kim, June-Key Chung

    The authors evaluated whether the cytotoxicity of CD8+CTLs generated by combined hMUC1 vaccination and hNIS radioiodine gene therapy was enhanced in the presence of CpG in an established tumor model. CMNF cells (CT26 cells expressing hMUC1, hNIS and Firefly luciferase) were transplanted into BALB/c mice. Four and 10 days later, tumor-bearing mice were immunized intramuscularly with pcDNA3.1 or pcDNA-hMUC1 or pcDNA-hMUC1+CpG, and subsequently administered PBS or 131I [five groups (seven mice/group): referred to as the pcDNA3.1+PBS, phMUC1+PBS, pcDNA3.1+131I, phMUC1+131I, and phMUC1+131I+CpG groups]. The number of CD8+IFNr+ T cells of splenocytes as well as the number of CD8+IFNr+ T cells of splenocytes re-stimulated with CD11c+ cells was determined using FACS analysis. The activities of cytotoxic T cells (CTLs) from splenocytes were investigated. Marked tumor growth inhibition was observed in the phMUC1+131I and phMUC1+131I+CpG groups, but not in the other three single therapy groups. Particularly the number of CD8+IFN-γ+ T cells of splenocytes was more increased in the phMUC1+131I+CpG group than in the phMUC1+131I group. The number of CD8+IFN-γ+ T cells of splenocytes stimulated with CD11c+ cells was the most enhanced in the phMUC1+131I+CpG group among the five groups. Concurrently, the activities of hMUC1-associated CTLs obtained from splenocytes in the phMUC1+131I+CpG group were significantly greater than in the other four groups (pcDNA+PBS, phMUC1+PBS, pcDNA+131I, phMUC1+131I, and phMUC1+131I+CpG, 16 ± 2%, 20 ± 1%, 30 ± 2%, 60 ± 2%, and 87 ± 2%, respectively, P < 0.01). Our data suggest that adjuvant CpG ODNs can increase the killing activities of CTLs generated by combined hMUC1 DNA vaccination and hNIS radioiodine gene therapy.


  • Nuclear Factor-Kappa B Inhibition Reduces Markedly Cell Proliferation in Epstein-Barr Virus-Infected Stomach Cancer, But Affects Variably in Epstein-Barr Virus-Negative Stomach Cancer

    by Jin-Yong Jeong, Jun Hee Woo, Yang Soo Kim, Sangho Choi, Sang Oh Lee, Seol-Ryoung Kil, Chul Woo Kim, Byung Lan Lee, Woo Ho Kim, Byung-Ho Nam, et al.

    Nuclear factor-kappa B (NF-κB) inhibition by NF-κB p65-specific siRNA induced a near-cessation of cell proliferation in EBV-positive stomach cancer cell, and notably diminished cell proliferation in EBV- positive Raji lymphoma cell. In EBV-negative stomach cancer cells, NF-κB inhibition affected variably cell proliferation. Regardless of cell type, NF-κB inhibition suppressed antiapoptotic function of NF-κB, and tended to promote the nuclear accumulation of beta-catenin. This inverse relationship between NF-κB and beta-catenin was evident in 120 resected gastric carcinomas. Conclusively, NF-κB inhibition may be beneficial in the therapy of EBV-positive stomach cancer, but influence variously EBV-negative stomach cancer.


  • Nuclear Factor-Kappa B Inhibition Reduces Markedly Cell Proliferation in Epstein-Barr Virus-Infected Stomach Cancer, But Affects Variably in Epstein-Barr Virus-Negative Stomach Cancer

    by Jin-Yong Jeong, Jun Hee Woo, Yang Soo Kim, Sangho Choi, Sang Oh Lee, Seol-Ryoung Kil, Chul Woo Kim, Byung Lan Lee, Woo Ho Kim, Byung-Ho Nam, et al.

  • MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type

    by S O Yoon, Y K Jeon, J H Paik, W Y Kim, Y A Kim, J E Kim, C W Kim

    Aims:  Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease with various genetic alterations. The aim was to investigate MYC, Bcl‐2 and Bcl‐6 translocations and copy number changes in adult DLBCLs to evaluate their clinicopathological features and prognostic implications.Methods and results:  Gene status was examined using fluorescence in situ hybridization (FISH), and the results were analysed in the context of germinal centre B‐cell (GCB) and non‐GCB type of DLBCL based on immunohistochemistry. MYC translocation was observed in 9% (14 of 156), and an increased copy number (ICN) in 7.1% (11 of 156). MYC translocation was more common in GCB type (22%) than in non‐GCB type (4.9%), and associated with advanced International Prognostic Index (IPI). MYC aberration, i.e. translocation or increased copy number (ICN), was significantly associated with shorter overall survival, especially for the GCB type. Bcl‐2 translocation was rare (3.4%, five of 145), and ICN was observed in 11.7% (17 of 145), more frequently in non‐GCB type (16%) than in GCB type (2.5%). Bcl‐2 aberration tended to have an adverse effect on survival. In multivariate analysis, MYC ICN was an independent poor prognostic factor.Conclusions:  Analyses of MYC and Bcl‐2 status, i.e. translocation and ICN, in the context of DLBCL phenotype might help predict prognosis and determine therapeutic strategies.


  • Open Access

    Over-expression of Adenine Nucleotide Translocase 1 (ANT1) Induces Apoptosis and Tumor Regression in vivo

    by Ji-Young Jang, Yun Choi, Yoon-Kyung Jeon, Khin Chaw Ayu Aung, Chul-Woo Kim

    Background: Adenine nucleotide translocase (ANT) is located in the inner mitochondrial membrane and catalyzes the exchange of mitochondrial ATP for cytosolic ADP. ANT has been known to be a major component of the permeability transition pore complex of mitochondria and contributes to mitochondria-mediated apoptosis. Human ANT has four isoforms (ANT1, ANT2, ANT3, and ANT4), and the expression of the ANT isoforms is variable depending on the tissue and cell type, developmental stage, and proliferation status. Among the isoforms, ANT1 is highly expressed in terminally-differentiated tissues, but expressed in low levels in proliferating cells, such as cancer cells. In particular, over-expression of ANT1 induces apoptosis in cultured tumor cells. Methods: We applied an ANT1 gene transfer approach to induce apoptosis and to evaluate the anti-tumor effect of ANT1 in a nude mouse model. Results: We demonstrated that ANT1 transfection induced apoptosis of MDA-MB-231 cells, inactivated NF-κB activity, and increased Bax expression. ANT1-inducing apoptosis was accompanied by the disruption of mitochondrial membrane potential, cytochrome c release and the activation of caspases-9 and -3. Moreover, ANT1 transfection significantly suppressed tumor growth in vivo. Conclusion: Our results suggest that ANT1 transfection may be a useful therapeutic modality for the treatment of cancer.


  • Open Access

    Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo

    by Ji-Young Jang, Yun Choi, Yoon-Kyung Jeon, Chul-Woo Kim

    Introduction: Adenine nucleotide translocator (ANT) 2 is highly expressed in proliferative cells, and ANT2 induction in cancer cells is known to be directly associated with glycolytic metabolisms and carcinogenesis. In addition, ANT2 repression results in the growth arrest of human cells, implying that ANT2 is a candidate for cancer therapy based on molecular targeting. Methods: We utilized an ANT2-specific RNA interference approach to inhibit ANT2 expression for evaluating its antitumor effect in vitro and in vivo. Specifically, to investigate the therapeutic potential of ANT2 repression, we used a DNA vector-based RNA interference approach by expressing shRNA to knockdown ANT2 in breast cancer cell lines overexpressing ANT2. Results: ANT2 shRNA treatment in breast cancer cell line MDA-MB-231 repressed cell growth as well as proliferation. In addition, cell cycle arrest, ATP depletion and apoptotic cell death characterized by the potential disruption of mitochondrial membrane were observed from the ANT2 shRNA-treated breast cancer cells. Apoptotic breast cancer cells transfected with ANT2 shRNA also induced a cytotoxic bystander effect that generates necrotic cell death to the neighboring cells. The intracellular levels of TNFα and TNF-receptor I were increased in ANT2 shRNA transfected cells and the bystander effect was partly blocked by anti-TNFα antibody. Ultimately, ANT2 shRNA effectively inhibited tumor growth in vivo. Conclusion: These results suggest that vector-based ANT2 RNA interference could be an efficient molecular therapeutic method for breast cancer with high expression of ANT2.


  • The heat‐shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein–Barr virus‐positive NK/T‐cell lymphoma by Akt down‐regulation

    by Yk Jeon, Ch Park, K‐Y Kim, Yc Li, J Kim, Ya Kim, J‐H Paik, B‐K Park, C‐W Kim, Y‐N Kim

    NK/T‐cell lymphoma (NKTL) is strongly associated with latent Epstein–Barr virus (EBV) infection. Recently, latent membrane protein 1 (LMP1), an EBV oncoprotein, was reported to activate the phosphatidylinositol‐3 kinase (PI3K)/Akt pathway for cell survival. Because geldanamycin (GA) and its derivative, 17‐allylamino‐17‐demethoxygeldanamycin (17‐AAG), exhibit anti‐tumour activity by degrading HSP90 client proteins, including Akt, we investigated the effect of GA and 17‐AAG on the survival of NKTL cell lines. EBV‐positive NKTL cell lines, Hank‐1 and NK‐YS, and an EBV‐negative NK leukaemia cell line, NK‐L, were treated with PI3K and Akt inhibitors, GA, and 17‐AAG, and were subjected to apoptosis and cell viability assays, and immunoblot analysis. EBV‐positive B‐lymphoblastoid cell lines IM9 and LMP1‐transfected IM9 (IM9‐LMP1) were also included. Hank‐1 and NK‐YS cell viability was compromised and apoptosis was induced by LY294002 (PI3K inhibitor) or Akt inhibitor II. GA or 17‐AAG administration resulted in the apoptosis of NKTL cells, accompanied by Akt and pAkt down‐regulation, caspase 3 activation, and mitochondrial membrane potential disruption. The intrinsic level of pAkt was higher in EBV‐positive NKTL cells than in EBV‐negative NK‐L, and GA or 17‐AAG decreased the viability of NKTL cells more efficiently than NK‐L. Moreover, IM9‐LMP1 was more sensitive to Akt inhibitor II or HSP90 inhibitors than IM9. Importantly, GA showed little effect on the viability of normal peripheral NK cells as non‐neoplastic counterparts for comparison. In conclusion, this study suggests that the PI3K/Akt pathway is frequently activated in EBV‐positive NKTL and that therapeutic modalities based on targeting the PI3K/Akt pathway with HSP90 inhibitors could be useful for achieving NKTL control. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


    • 1 May 2007
      • Vol. 27  (2) , 785-91

    Role and prognostic significance of proapoptotic proteins in Epstein-Barr virus-infected gastric carcinomas.

    by Mee Soo Chang, Hye Seung Lee, Eun Ji Jung, Chul Woo Kim, Byung Lan Lee, Woo Ho Kim

    The purposes of the present study were to evaluate the role and the prognostic values of proapoptotic proteins involved in the death receptors (Fas and TRAIL receptors) and mitochondrial pathways (Bax) in Epstein-Barr virus (EBV)-infected gastric carcinomas. Fifty-five EBV-infected gastric carcinomas were identified by in situ hybridization for EBV-encoded small RNAs. Immunohistochemistry was performed for Fas, Fas-ligand, FADD, TRAIL, DR4, DR5 and Bax. Apoptotic indices (AIs) were determined using TUNEL assay and assessed. No remarkable differences in protein expressions were observed between EBV-infected gastric carcinomas and conventional gastric carcinomas. Bax positivity tended to be associated with higher AI (p = 0.068), whereas Fas and FADD positivities were related to lower AI (p = 0.006 and 0.059, respectively). Proteins involved in TRAIL pathways showed no statistical significant relationship with AI. TNM stage and Fas and FADD expressions were related to overall survival (p < 0.05), but TNM stage was the only independent prognostic factor. Apoptosis in EBV-infected gastric carcinomas probably occurs via the mitochondrial pathway through Bax, rather than via the death receptor pathways. Fas and FADD expressions, and pathological tumor stage (TNM stage) may be the prognostic factors.